Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies-Reference-Cited by-同舟云学术

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies

Published:2016-08-20 Issue:3 Volume:6 Page:503-517
ISSN:1877-7171
Container-title:Journal of Parkinson's Disease
language:
Short-container-title:JPD

Author:

Pagan Fernando¹,Hebron Michaeline²,Valadez Ellen H.¹,Torres-Yaghi Yasar¹,Huang Xu²,Mills Reversa R.¹,Wilmarth Barbara M.¹,Howard Hellen¹,Dunn Connell¹,Carlson Alexis¹,Lawler Abigail¹,Rogers Sean L.¹,Falconer Ramsey A.¹,Ahn Jaeil³,Li Zhaoxia¹,Moussa Charbel²¹

Affiliation:

1. Department of Neurology, National Parkinson’s Foundation Center for Excellence, Translational Neurotherapeutics Program. Movement Disorders Program. MedStar Georgetown Hospital Washington, DC, USA

2. Department of Neurology, Laboratory for Dementia and Parkinsonism, National Parkinson’s Foundation Center for Excellence, Translational Neurotherapeutics Program. Georgetown University Medical Center, Washington, DC, USA

3. Department of Biostatistics, Georgetown University Medical Center, Washington, DC, USA

Publisher

IOS Press

Subject

Cellular and Molecular Neuroscience,Neurology (clinical)

Reference48 articles.

1. Autophagy induction and autophagosome clearance in neurons: Relationship to autophagic pathology in Alzheimer’s disease;Boland;J Neurosci,2008

2. Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy;Kegel;J Neurosci,2000

3. Extensive involvement of autophagy in Alzheimer disease: An immuno-electron microscopy study;Nixon;J Neuropathol Exp Neurol,2005

4. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy;Ravikumar;Hum Mol Genet,2002

5. mTOR and cancer: Insights into a complex relationship;Sabatini;Nat Rev Cancer,2006

Cited by 215 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies;Cellular and Molecular Life Sciences;2024-09-03

2. Current Therapeutic Options and Repurposed Drugs for Neurodegeneration;Advances in Diagnostics and Immunotherapeutics for Neurodegenerative Diseases;2024-07-28

3. The Role of Alpha-Synuclein and Tubulin-Associated Unit (Tau) Proteins in the Diagnosis, Prognosis, and Treatment of Parkinson’s Disease: A Systematic Review;Cureus;2024-07-17

4. Advances in Clinical Therapies for Huntington's Disease and the Promise of Multi‐Targeted/Functional Drugs Based on Clinicaltrials.gov;Clinical Pharmacology & Therapeutics;2024-06-11

5. Neuroprotective Activity of a Non-Covalent Imatinib+TP10 Conjugate in HT-22 Neuronal Cells In Vitro;Pharmaceutics;2024-06-07